Xtx Topco LTD Bio N Tech Se Transaction History

Xtx Topco LTD

$1.3 Billion
Q3 2024

A detailed history of Xtx Topco LTD transactions in Bio N Tech Se stock. As of the latest transaction made, Xtx Topco LTD holds 3,862 shares of BNTX stock, worth $385,118. This represents 0.04% of its overall portfolio holdings.

Number of Shares

3,862

Holding current value

$385,118

% of portfolio

0.04%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$78.36 - $124.66 $302,626 - $481,436	3,862 New	3,862 $458,000
Q1 2024 May 13, 2024	BUY	$88.96 - $112.35 $463,837 - $585,792	5,214 New	5,214 $480,000
Q2 2023 Aug 14, 2023	SELL	$102.58 - $129.66 $372,057 - $470,276	-3,627 Reduced 51.9%	3,362 $362,000
Q1 2023 May 12, 2023	BUY	$122.57 - $153.67 $641,408 - $804,155	5,233 Added 298.01%	6,989 $870,000
Q4 2022 Feb 14, 2023	SELL	$118.43 - $186.05 $1.05 Million - $1.66 Million	-8,897 Reduced 83.52%	1,756 $263,000
Q3 2022 Nov 14, 2022	BUY	$127.65 - $183.11 $1.03 Million - $1.47 Million	8,038 Added 307.38%	10,653 $1.44 Million
Q2 2022 Aug 15, 2022	BUY	$123.25 - $186.24 $322,298 - $487,017	2,615 New	2,615 $390,000
Q1 2022 May 13, 2022	SELL	$126.25 - $231.85 $231,290 - $424,749	-1,832 Closed	0 $0
Q4 2021 Feb 11, 2022	BUY	$216.64 - $362.52 $396,884 - $664,136	1,832 New	1,832 $472,000
Q3 2021 Nov 12, 2021	SELL	$205.93 - $447.23 $258,648 - $561,720	-1,256 Closed	0 $0
Q2 2021 Aug 12, 2021	SELL	$113.32 - $241.49 $301,771 - $643,087	-2,663 Reduced 67.95%	1,256 $281,000
Q1 2021 May 14, 2021	BUY	$85.73 - $119.5 $335,975 - $468,320	3,919 New	3,919 $428,000

Others Institutions Holding BNTX

# of Institutions

358

Shares Held

38.4M

Call Options Held

2.45M

Put Options Held

2.29M

View Full List

About BioNTech SE

Ticker BNTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 242,684,992
Market Cap $24.2B
Description
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...

More about BNTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Xtx Topco LTD, based on Form 13F filings with the SEC.

News

Stay updated on Xtx Topco LTD with notifications on news.

Account